Robert Rosen will lead the launch of APF530, AP Pharma’s drug to prevent chemotherapy-induced nausea and vomiting.
He will become a director of the company once the drug has successfully establishes a market presence.
John Whelan, President and CEO of AP Pharma, said: “Robert’s deep and extensive experience commercialising oncology drugs will be instrumental as we enter the commercialisation phase of the company.”
AP Pharma specialises in developing injectable drugs using its Biochronomer polymer-based drug delivery platform, which can reduce the frequency of injection from daily to weekly or fortnightly.
APF30, the company’s lead product, is used to prevent both acute-onset and delayed-onset nausea and vomiting caused by chemotherapy.
Rosen led Bayer’s cancer drugs operation from 2005 to 2011 – including the launch of Nexavar (sorafenib) for the treatment of renal cancers.
Before that, he was VP of oncology at Sanofi-Synthèlabo, where he was responsible for launching the colon cancer drug Eloxatin (oxaliplatin).